Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04120766 · ClinicalTrials.gov registry record · Phase 2
Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging
A Phase 2 study of Mild Cognitive Impairment and Dementia, sponsored by Gregory Jicha, MD, PhD.
- Active
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT04120766: Active Phase 2 study of Mild Cognitive Impairment and Dementia, sponsored by Gregory Jicha, MD, PhD.
NCT04120766 is a Phase 2 study of Mild Cognitive Impairment and Dementia that is active but no longer recruiting, run by Gregory Jicha, MD, PhD. The registered enrollment target is 64 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04120766, a Phase 2 study of Mild Cognitive Impairment and Dementia, is active but no longer recruiting, sponsored by Gregory Jicha, MD, PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
Widespread recognition of the current and projected impact of the dementia epidemic has spurred research into novel drug discovery efforts. It is well recognized by most that Alzheimer's disease is not the only form of dementia and that beginning to turn attention to other disease states is critically important in order to alleviate this burden on the elderly population today This proposal seeks to further progress in this area through the repurposing an existing drug therapy as a potential treatment for Hippocampal Sclerosis of Aging. This disease is seldom recognized clinically and yet is the number one Alzheimer's disease mimic the confounds are diagnostic and treatment of subjects suffering from dementia and as of yet has no potential therapeutic interventions identified. As such, the proposed study represents a cutting-edge, data-driven, low-cost, exploration of a novel disease relevant pathway that may hold promise for global efforts targeting late life dementia which is a major health priority in America today.
Primary Outcome
Safety
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nicorandil
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 2 |
What the registry record for NCT04120766 still lists
NCT04120766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04120766 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT04120766 about?
NCT04120766 is a clinical study titled "Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging". Widespread recognition of the current and projected impact of the dementia epidemic has spurred research into novel drug discovery efforts. It is well recognized by most that Alzheimer's disease is not the only form of dementia and that beginning to turn attention to other disease states is critical...
What is the current status of trial NCT04120766?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2021-12-01. Estimated completion is 2026-11-30.
What conditions does trial NCT04120766 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Dementia.
What interventions are being tested in trial NCT04120766?
The interventions under investigation include: Placebo (DRUG), Nicorandil (DRUG).
Who is sponsoring clinical trial NCT04120766?
This trial is sponsored by Gregory Jicha, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04120766 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04120766's enrollment target sits among peer trials
64 121st of 205 higher than 84 of 205 other Mild Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)
RECRUITING · Phase 2
-
The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study
RECRUITING · Phase 2
-
Rapamycin - Effects on Alzheimer's and Cognitive Health
RECRUITING · Phase 2
-
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
RECRUITING · Phase 2
-
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI